Karius, Inc., a pioneer in genomic diagnostics for infectious diseases, has received a Breakthrough Device designation from the FDA for its Karius Test. This designation recognizes the test’s potential in diagnosing and managing lung infections in immunocompromised patients, including lower respiratory infections and pneumonia.
The Karius Test utilizes metagenomic sequencing to identify pathogens efficiently and accurately. Clinical data from the PICKUP study demonstrate its ability to detect the cause of pneumonia in immunocompromised patients with 40% higher precision than conventional methods.
The Breakthrough Device Program expedites developing and reviewing innovative medical devices that offer promising solutions for life-threatening or debilitating conditions. The Karius Test has shown significant value in improving the diagnosis and treatment of immunocompromised patients with lung infections.
The test’s ability to identify non-pneumonia infections underscores the limitations of traditional diagnostic approaches that rely solely on clinical symptoms. By utilizing a pathogen- and site-agnostic approach, the Karius Test provides broader diagnostic capabilities.
Expert opinion from Norman E. Sharpless, former Director of the National Cancer Institute, highlights the test’s potential to transform the care of immunocompromised patients with hematologic cancers and undergoing stem cell transplantation.
Ongoing research, including data on the Karius Test’s cost-effectiveness, will be presented at the American Thoracic Society Annual Meeting 2024 International Conference. These findings further support the Karius Test’s significant impact on improving diagnostic accuracy and patient outcomes for this vulnerable population.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
